RedHill Biopharma (RDHL) Provides R&D Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/10/2026
- Wall St ticks lower as markets monitor Hormuz situation; data awaited
- JPMorgan lifts S&P 500 target to 8,000 on strong earnings
- Jefferies cuts Apple rating as higher-priced iPhone roadmap looks difficult
- Oil rises nearly 2% as Iran tempers hopes of Hormuz reopening
- Intel stock stumbles following blockbuster $15 billion equity offering
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
- After-Hours Stock Movers: PLTR, SNAP, ON, ICHR, WGS, WHR
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
RedHill Provides R&D Update
May 22, 2023 7:00 AM EDTRedHill has elected to terminate RHB-204's U.S. Phase 3 study for Non-tuberculosis Mycobacteria (NTM) disease due to low accrual rate and plans to shift resources to more rapidly advance RHB-107 late-stage development for outpatient treatment of COVID-19
RedHill's advanced pipeline also includes: Opaganib in collaboration with the U.S. Government's Radiation and Nuclear Countermeasures Program for development as a potential treatment for Acute Radiation Syndrome (ARS) and... More
